{"mtb_report":
{
  "patient": {
    "id": "1",
    "age": null,
    "sex": "F",
    "birth_date": null
  },
  "diagnosis": {
    "primary_diagnosis": "carcinoma tiroideo",
    "stage": null,
    "histology": null,
    "icd_o_code": {
      "code": "8010/3",
      "system": "ICD-O-3",
      "display": "Carcinoma, NOS",
      "topography": "C73"
    }
  },
  "variants": [
    {
      "gene": "KRAS",
      "cdna_change": null,
      "protein_change": "G12D",
      "classification": null,
      "vaf": 25.0,
      "raw_text": null,
      "gene_code": {
        "code": "HGNC:6407",
        "system": "http://www.genenames.org",
        "name": "KRAS Proto-Oncogene, GTPase",
        "chromosome": "12",
        "cancer_types": [
          "NSCLC",
          "Colorectal",
          "Pancreatic"
        ],
        "actionable": true
      }
    },
    {
      "gene": "KRAS",
      "cdna_change": null,
      "protein_change": "ed in particolare della variante G13V (che ha valore di gain of function) in pazienti con MET exon skipping non è riportata in letteratura; tuttavia alterazioni di KRAS sono descritte come meccanismi di resistenza primaria e secondaria agli inibitori di MET",
      "classification": null,
      "vaf": null,
      "raw_text": null,
      "gene_code": {
        "code": "HGNC:6407",
        "system": "http://www.genenames.org",
        "name": "KRAS Proto-Oncogene, GTPase",
        "chromosome": "12",
        "cancer_types": [
          "NSCLC",
          "Colorectal",
          "Pancreatic"
        ],
        "actionable": true
      }
    },
    {
      "gene": "STRN::ALK",
      "cdna_change": null,
      "protein_change": "fusion",
      "classification": "Pathogenic",
      "vaf": 3.0,
      "raw_text": null,
      "gene_code": {
        "code": "HGNC:11425",
        "system": "http://www.genenames.org",
        "name": "Striatin",
        "chromosome": "2",
        "cancer_types": [
          "Various"
        ],
        "actionable": false
      }
    }
  ],
  "recommendations": [
    {
      "drug": "alectinib",
      "gene_target": "ALK",
      "evidence_level": "FDA Approved",
      "clinical_trial": null,
      "rationale": null,
      "drug_code": {
        "code": "1721520",
        "system": "RxNorm",
        "display": "alectinib",
        "target": [
          "ALK"
        ],
        "indication": "ALK-positive NSCLC",
        "evidence_level": "FDA Approved"
      }
    },
    {
      "drug": "niraparib",
      "gene_target": "BRCA1, BRCA2",
      "evidence_level": "FDA Approved",
      "clinical_trial": null,
      "rationale": null,
      "drug_code": {
        "code": "1856219",
        "system": "RxNorm",
        "display": "niraparib",
        "target": [
          "BRCA1",
          "BRCA2"
        ],
        "indication": "BRCA-mutated ovarian cancer",
        "evidence_level": "FDA Approved"
      }
    },
    {
      "drug": "capmatinib",
      "gene_target": "MET",
      "evidence_level": "FDA Approved",
      "clinical_trial": null,
      "rationale": null,
      "drug_code": {
        "code": "2379709",
        "system": "RxNorm",
        "display": "capmatinib",
        "target": [
          "MET"
        ],
        "indication": "MET exon 14 skipping NSCLC",
        "evidence_level": "FDA Approved"
      }
    },
    {
      "drug": "tepotinib",
      "gene_target": "MET",
      "evidence_level": "FDA Approved",
      "clinical_trial": null,
      "rationale": null,
      "drug_code": {
        "code": "2468669",
        "system": "RxNorm",
        "display": "tepotinib",
        "target": [
          "MET"
        ],
        "indication": "MET exon 14 skipping NSCLC",
        "evidence_level": "FDA Approved"
      }
    },
    {
      "drug": "erdafitinib",
      "gene_target": "FGFR2, FGFR3",
      "evidence_level": "FDA Approved",
      "clinical_trial": null,
      "rationale": null,
      "drug_code": {
        "code": "2177997",
        "system": "RxNorm",
        "display": "erdafitinib",
        "target": [
          "FGFR2",
          "FGFR3"
        ],
        "indication": "FGFR-altered urothelial carcinoma",
        "evidence_level": "FDA Approved"
      }
    }
  ],
  "tmb": null,
  "ngs_method": "genomico interno solo quella di TP53 è stata classificata come di significato patogenetico, mentre per le alterazioni di BAP1, NF1 e PTEN altresì riscontrate non ci sono ad oggi evidenze di significato clinico riportate nei principali database di riferimento.",
  "report_date": null,
  "quality_metrics": {
    "total_fields": 15,
    "filled_fields": 3,
    "completeness_pct": 20.0,
    "variants_found": 3,
    "variants_with_vaf": 2,
    "variants_classified": 1,
    "variants_with_gene_code": 3,
    "drugs_identified": 5,
    "drugs_mapped": 5,
    "diagnosis_mapped": true,
    "patient_complete": false,
    "warnings": [
      "Patient information incomplete",
      "TMB not found"
    ]
  }
}}
